Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2021 Oct 22

PMID 34675653

Citations 9

Authors

Yousef M Al-Saraireh

Fatemah O F O Alshammari

Ahmed M M Youssef

Fatima Al-Tarawneh

Sameeh Al-Sarayreh

Ghadeer H Almuhaisen

Anas O Satari

Jehad Al-Shuneigat

Hamzeh Mohammad Alrawashdeh

Affiliations

Soon will be listed here.

Abstract

Purpose: Triple-negative breast cancer (TNBC) is characterized by high mortality rate, and its clinical management is difficult and complex. Therefore, there is a need for extensive efforts aimed at accelerating the discovery of novel therapies for TNBC. CYP4Z1 has been implicated in the development of breast cancer. The current study aimed at characterizing the expression of CYP4Z1 on TNBC.

Materials And Methods: Using immunohistochemistry, CYP4Z1 expression was evaluated on 122 TNBC samples, four samples of breast cancers expressing ER, PR, and HER-2, and four samples of normal breast tissues. The association between the enzyme and various histopathological features and survival of patients were determined.

Results: CYP4Z1 was strongly expressed in 83.3% of various histopathological subtypes of TNBC, when compared to negative expression in normal breast tissues. Interestingly, there were marked variations in CYP4Z1 expression with respect to histopathology subtype, histological grade, histological stage and tumor diameter. There was a high incidence of CYP4Z1 expression in patients with advanced grades, late stages and larger tumor sizes. Importantly, CYP4Z1 expression was correlated with the survival of TNBC patients, but it was an independent determinant of the poor prognosis of TNBC (p< 0.05).

Conclusion: CYP4ZI may be a potential biomarker or target for evolving new CYP4Z1-targeted treatments.

Citing Articles

Lai J, Huang R, Huang J Front Immunol. 2025; 16:1536284.

PMID: 39958347 PMC: 11825753. DOI: 10.3389/fimmu.2025.1536284.

The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and review.

Leahy C, Osborne N, Shirota L, Rote P, Lee Y, Song B Biochem Pharmacol. 2024; 228:116241.

PMID: 38697309 PMC: 11774579. DOI: 10.1016/j.bcp.2024.116241.

Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches.

Pastena P, Perera H, Martinino A, Kartsonis W, Giovinazzo F Int J Mol Sci. 2024; 25(5).

PMID: 38473804 PMC: 10931553. DOI: 10.3390/ijms25052559.

Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention.

Al-Saraireh Y, Alshammari F, Abu-Azzam O, Al-Dalain S, Al-Sarayra Y, Haddad M Biomedicines. 2023; 11(11).

PMID: 38001897 PMC: 10669316. DOI: 10.3390/biomedicines11112898.

Improved methods for the detection of heme and protoporphyrin IX adducts and quantification of heme B from cytochrome P450 containing systems.

Pelletier R, Rettie A, Kowalski J J Chromatogr B Analyt Technol Biomed Life Sci. 2023; 1231:123921.

PMID: 37956555 PMC: 10842765. DOI: 10.1016/j.jchromb.2023.123921.

References

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

Tradonsky A, Rubin T, Beck R, Ring B, Seitz R, Mair S . A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases. Am J Clin Pathol. 2012; 137(6):918-30. DOI: 10.1309/AJCPF3QWIG8FWXIH. View

Yu W, Chai H, Li Y, Zhao H, Xie X, Zheng H . Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer. Toxicol Appl Pharmacol. 2012; 264(1):73-83. PMC: 3439529. DOI: 10.1016/j.taap.2012.07.019. View

Zheng L, Li X, Meng X, Chou J, Hu J, Zhang F . Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer. Mol Cell Endocrinol. 2016; 427:133-42. DOI: 10.1016/j.mce.2016.03.012. View

Al-Saraireh Y, Alshammari F, Youssef A, Al-Sarayreh S, Almuhaisen G, Alnawaiseh N . Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers. Sci Rep. 2021; 11(1):5581. PMC: 7946900. DOI: 10.1038/s41598-021-85188-4. View

Luo J, Feng X, Luo C, Wang Y, Li D, Shu Y . 14,15-EET induces the infiltration and tumor-promoting function of neutrophils to trigger the growth of minimal dormant metastases. Oncotarget. 2016; 7(28):43324-43336. PMC: 5190026. DOI: 10.18632/oncotarget.9709. View

Al-Saraireh Y, Alboaisa N, Alrawashdeh H, Hamdan O, Al-Sarayreh S, Al-Shuneigat J . Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues. Ecancermedicalscience. 2020; 14:1114. PMC: 7581338. DOI: 10.3332/ecancer.2020.1114. View

Bruno R, Njar V . Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem. 2007; 15(15):5047-60. PMC: 1958998. DOI: 10.1016/j.bmc.2007.05.046. View

Allred D . Problems and solutions in the evaluation of hormone receptors in breast cancer. J Clin Oncol. 2008; 26(15):2433-5. DOI: 10.1200/JCO.2007.15.7800. View

10.

Zollner A, Dragan C, Pistorius D, Muller R, Bode H, Peters F . Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid. Biol Chem. 2008; 390(4):313-7. DOI: 10.1515/BC.2009.030. View

11.

Downie D, McFadyen M, Rooney P, Cruickshank M, Parkin D, Miller I . Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res. 2005; 11(20):7369-75. DOI: 10.1158/1078-0432.CCR-05-0466. View

12.

Khayeka-Wandabwa C, Ma X, Cao X, Nunna V, Pathak J, Bernhardt R . Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans. Int Immunopharmacol. 2019; 73:64-71. DOI: 10.1016/j.intimp.2019.05.003. View

13.

Murray G, Patimalla S, Stewart K, Miller I, Heys S . Profiling the expression of cytochrome P450 in breast cancer. Histopathology. 2010; 57(2):202-11. DOI: 10.1111/j.1365-2559.2010.03606.x. View

14.

Al-Saraireh Y, Alshammari F, Youssef A, Al-Sarayra Y, Al-Saraireh R, Al-Muhaisen G . Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer. Curr Oncol. 2021; 28(5):3573-3584. PMC: 8482276. DOI: 10.3390/curroncol28050306. View

15.

Panigrahy D, Greene E, Pozzi A, Wang D, Zeldin D . EET signaling in cancer. Cancer Metastasis Rev. 2011; 30(3-4):525-40. PMC: 3804913. DOI: 10.1007/s10555-011-9315-y. View

16.

Yan Q, Machalz D, Zollner A, Sorensen E, Wolber G, Bureik M . Efficient substrate screening and inhibitor testing of human CYP4Z1 using permeabilized recombinant fission yeast. Biochem Pharmacol. 2017; 146:174-187. DOI: 10.1016/j.bcp.2017.09.011. View

17.

McDonald M, Ray S, Amorosi C, Sitko K, Kowalski J, Paco L . Expression and Functional Characterization of Breast Cancer-Associated Cytochrome P450 4Z1 in . Drug Metab Dispos. 2017; 45(12):1364-1371. PMC: 5697098. DOI: 10.1124/dmd.117.078188. View

18.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

19.

Kowalski J, McDonald M, Pelletier R, Hanenberg H, Wiek C, Rettie A . Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1. J Med Chem. 2020; 63(9):4824-4836. DOI: 10.1021/acs.jmedchem.0c00101. View

20.

Cocco S, Piezzo M, Calabrese A, Cianniello D, Caputo R, Lauro V . Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. Int J Mol Sci. 2020; 21(13). PMC: 7369987. DOI: 10.3390/ijms21134579. View